Dermatologic Manifestations of Peyronie Disease Follow-up
- Author: Anne Elizabeth Laumann, MBChB, MRCP(UK), FAAD; Chief Editor: Dirk M Elston, MD more...
Further Outpatient Care
Radiation treatment may be recommended for early, especially painful situations. Radiation from a beta-beam linear accelerator is used to reduce inflammation. This treatment does not change or remove late-stage postinflammatory plaques.
Extracorporeal shock-wave therapy may help in treating the curvature associated with Peyronie disease. This treatment does not help the pain and is still experimental.
Theoretically, patients with Peyronie disease should avoid vigorous intercourse with a weak erection.
If the patient has diabetes, it should be controlled.
No method for absolute prevention is known.
Complications of Peyronie disease include the complete inability to maintain sexual performance.
The spectrum of Peyronie disease ranges from asymptomatic plaques to mild penile curvature or severe curvature that results in a complete inability to have sexual intercourse. Erectile pain can range from none to severe, depending on the site and amount of plaque deposition.
Peyronie disease only occasionally, if ever, disappears completely. The pain may diminish or resolve after the early inflammatory phase, and as many as 13% of patients claim to have some improvement with time. Approximately one half of the remaining individuals have progressive disease, whereas the other half have static disease.
Variable degrees of morbidity may occur. Conditions range from a static painless plaque without penile angulation to painful erections with a curvature significant enough to prevent sexual activity.
Data suggest a combination approach to therapy for Peyronie disease. For instance, the use of partially effective oral therapies with minimally invasive mechanical or intralesional treatments may be more successful than each individual therapy alone.
Patient education in Peyronie disease includes the following:
Reassurance that lesions are not cancerous or fatal
An explanation that the condition is not curable but that it is treatable and possibly self-resolving
An open discussion about the problems with intercourse, the possibility of the resumption of satisfactory sexual activity, and the reduction of pain
Devine CJ Jr, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. 1997 Jan. 157(1):285-90. [Medline].
Casabé A, Bechara A, Cheliz G, De Bonis W, Rey H. Risk factors of Peyronie's disease. What does our clinical experience show?. J Sex Med. 2011 Feb. 8(2):518-23. [Medline].
Lucattelli M, Lunghi B, Fineschi S, et al. A new mouse model of Peyronie's disease: an increased expression of hypoxia-inducible factor-1 target genes during the development of penile changes. Int J Biochem Cell Biol. 2008. 40(11):2638-48. [Medline].
Nachtsheim DA, Rearden A. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol. 1996 Oct. 156(4):1330-4. [Medline].
Nyberg LM Jr, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol. 1982 Jul. 128(1):48-51. [Medline].
Gualdieri L, Valentini G, Lupoli S, Giordano M. Peyronie's disease in systemic sclerosis. Report of two cases. J Rheumatol. 1988 Feb. 15(2):380-1. [Medline].
Stewart S, Malto M, Sandberg L, Colburn KK. Increased serum levels of anti-elastin antibodies in patients with Peyronie's disease. J Urol. 1994 Jul. 152(1):105-6. [Medline].
Hricak H, Marotti M, Gilbert TJ, et al. Normal penile anatomy and abnormal penile conditions: evaluation with MR imaging. Radiology. 1988 Dec. 169(3):683-90. [Medline].
Erdogru T, Boz A, Koksal T, et al. Penile scintigraphy with 99mTc-human immunoglobulin G: a novel method for distinguishing the unstable and stable phases of Peyronie's disease. BJU Int. 2002 Nov. 90(7):703-6. [Medline].
Waldhauser M, Schr. P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol. 1988 Sep. 140(3):525-7. [Medline].
Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013 Jul. 190(1):199-207. [Medline].
Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int. 2009 Oct 26. [Medline].
Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001 Jul. 88(1):63-7. [Medline].
Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol. 2004 Apr. 171(4):1605-8. [Medline].
Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994 Jun. 151(6):1522-4. [Medline].
Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol. 2002 Aug. 168(2):621-5; discussion 625-6. [Medline].
Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl. 1999 Jul-Aug. 20(4):444-8. [Medline].
Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ. Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease. South Med J. 2004 Jan. 97(1):42-6. [Medline].
Polat O, Gul O, Ozbey I, Ozdikici M, Bayraktar Y. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol. 1997. 29(4):465-71. [Medline].
Montorsi F, Salonia A, Guazzoni G, et al. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J Androl. 2000 Jan-Feb. 21(1):85-90. [Medline].
Morgan RJ, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie's disease. Br J Urol. 1978 Apr. 50(2):111-3. [Medline].
Oosterlinck W, Renders G. Treatment of Peyronie's disease with procarbazine. Br J Urol. 1975 Apr. 47(2):219-20. [Medline].
Hauck EW, Altinkilic BM, Ludwig M, et al. Extracorporal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol. 2000 Dec. 38(6):663-9;discussion 670. [Medline].
Husain J, Lynn NN, Jones DK, Collins GN, O'Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. BJU Int. 2000 Sep. 86(4):466-8. [Medline].
Incrocci L, Hop WC, Seegenschmiedt HM. Radiotherapy for Peyronie's Disease: a European survey. Acta Oncol. 2008. 47(6):1110-2. [Medline].
Furlow WL, Swenson HE Jr, Lee RE. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol. 1975 Jul. 114(1):69-71. [Medline].
Yafi FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost LW, et al. The Effect of Duration of Penile Traction Therapy in Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease. J Urol. 2015 Sep. 194 (3):754-8. [Medline].
Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med. 2012 Jan. 9 (1):288-95. [Medline].
[Guideline] Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie's Disease: AUA Guideline. J Urol. 2015 Sep. 194 (3):745-53. [Medline].
Trussell JC, Brien JC. Straightening out Peyronie's: a medical and surgical approach to the patient. Can J Urol. 2008 Jun. 15(3):4047-55. [Medline].
Devine CJ Jr, Horton CE. Surgical treatment of Peyronie's disease with a dermal graff. J Urol. 1974 Jan. 111(1):44-9. [Medline].
Gangai MP, Rivera LR, Spence CR. Peyronie's plaque: excision and graft versus incision and stent. J Urol. 1982 Jan. 127(1):55-6. [Medline].
Wild RM, Devine CJ Jr, Horton CE. Dermal graft repair of Peyronie's disease: survey of 50 patients. J Urol. 1979 Jan. 121(1):47-50. [Medline].
Imbeault A, Bernard G, Ouellet G, Bouhout S, Carrier S, Bolduc S. Surgical option for the correction of Peyronie's disease: an autologous tissue-engineered endothelialized graft. J Sex Med. 2011 Nov. 8(11):3227-35. [Medline].
Knoll LD, Furlow WL, Benson RC Jr. Management of Peyronie disease by implantation of inflatable penile prosthesis. Urology. 1990 Nov. 36(5):406-9. [Medline].
Yafi FA, Sangkum P, McCaslin IR, Hellstrom WJ. Strategies for penile prosthesis placement in Peyronie's disease and corporal fibrosis. Curr Urol Rep. 2015 Apr. 16 (4):21. [Medline].
Fournier GR Jr, Lue TF, Tanagho EA. Peyronie's plaque: surgical treatment with the carbon dioxide laser and a deep dorsal vein patch graft. J Urol. 1993 May. 149(5 Pt 2):1321-5. [Medline].
Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol. 1959 Jun. 81(6):770-2. [Medline].
Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology. 1994 Aug. 44(2):291-5. [Medline].
Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992 Dec. 70(6):648-51. [Medline].